Phex Phriday Press Release: Patheon and DSM Combine Capabilities

DPx Launches as Global Provider of Pharmaceutical Services, Fine Chemicals and Proprietary Technologies

$2.65 billion transaction combines the capabilities and expertise of Patheon and DSM Pharmaceutical Products to create industry powerhouse

Durham, N.C. — (March 11, 2014)—DPx Holdings B.V. (DPx), privately owned by JLL Partners and Royal DSM, today launched as a leading global contract development and manufacturing organization (CDMO) for the pharmaceutical and related industries. DPx is the result of a USD $2.65 billion transaction between JLL Partners, a leading middle-market private equity firm, and Royal DSM, the global Life Sciences and Materials Sciences company. DPx is 51 percent owned by JLL Partners and 49 percent by Royal DSM. With headquarters in Durham, N.C., DPx’s global footprint includes 24 locations across North America, Europe, Latin America and Australia with more than 8,000 employees.

Formerly known by its provisional name “NewCo,” DPx is the corporate parent of a group of business units that is comprised of three distinct brands focused on pharmaceutical services, fine chemicals and products and proprietary technologies. These units are the result of combining DSM Pharmaceutical Products (DPP), Patheon and Banner Life Sciences.  The company’s business unit structure is as follows:

  • Pharmaceutical services will operate under the Patheon brand name and include the commercial manufacturing (CMO) capabilities, pharmaceutical product development services (PDS) as well as Biosolutions and Biologics (Bio) businesses of DPP;
  • Fine chemicals, or the ES/IM and active pharmaceutical ingredients (API) businesses, which will operate under the brand name DSM Fine Chemicals; and
  • Proprietary products and technologies, which will operate under the Banner Life Sciences brand name.

Patheon is the industry’s end-to-end supplier providing an integrated supply chain model to customers. Patheon delivers a full spectrum of pharmaceutical development and manufacturing services ranging from active pharmaceutical ingredients (API), Biologics and Biosolutions, as well as pharmaceutical product development services (PDS) and commercial manufacturing (CMO) capabilities. Additionally, DSM Fine Chemicals will handle complicated APIs and finished dosage forms for customers while Banner Life Sciences will offer its own proprietary and nutraceutical products to the market.

“This is an exciting day for our customers and employees. We believe that combining the capabilities and experience of both Patheon and DPP immediately positions us as the pharmaceutical industry’s partner of choice,” said Jim Mullen, CEO of DPx. “Today we are better positioned to add scale, new value chain capabilities and technologies, as well as expand our end-to-end service offerings to our customers as a global, comprehensive solution provider to the industry.”

Learn more and read the complete press release here.

Visit Patheon at their booth (1438) and DSM at booth (1211) at INTERPHEX, March 18 to 20!

Get the most out of the show by connecting with us on TwitterFacebook , LinkedIn and Google+



Official blog of: INTERPHEX New York -
This entry was posted in Uncategorized. Bookmark the permalink.

1 Response to Phex Phriday Press Release: Patheon and DSM Combine Capabilities

  1. Gsa ser list says:

    It’s going to be end of mine day, but before end I am reading this great article
    to increase my knowledge.

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s